Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.91 +0.2%	$12.77	$8.04 ▼ $45.00	$350.12M	3.41	455,904 shs	279,416 shs
IFRX InflaRx	$1.30 -1.5%	$1.22	$0.82 ▼ $2.82	$87.27M	2.21	226,009 shs	86,652 shs
TRDA Entrada Therapeutics	$8.84 -1.3%	$9.85	$7.10 ▼ $21.79	$332.34M	0.04	125,886 shs	96,288 shs
TSHA Taysha Gene Therapies	$1.76 -3.3%	$1.55	$1.05 ▼ $4.32	$360.90M	0.96	2.71 million shs	1.70 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+22.60%	+7.58%	-24.59%	-52.15%
IFRX InflaRx	0.00%	+22.64%	+4.00%	-44.44%	-4.41%
TRDA Entrada Therapeutics	0.00%	+8.73%	-11.24%	-31.15%	-28.88%
TSHA Taysha Gene Therapies	0.00%	+41.94%	-6.38%	+15.79%	-25.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.5494 of 5 stars	4.6	0.0	1.7	2.5	0.6
IFRX InflaRx	2.6593 of 5 stars	3.5	3.0	3.1	1.7	0.6
TRDA Entrada Therapeutics	3.1224 of 5 stars	3.6	3.0	3.2	1.7	1.3
TSHA Taysha Gene Therapies	2.1322 of 5 stars	3.5	0.0	3.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.13	Buy	$59.20	358.56% Upside
IFRX InflaRx	3.00	Buy	$9.00	592.31% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	190.35% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$6.63	276.42% Upside

Current Analyst Ratings Breakdown

Latest IFRX, TRDA, ARCT, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/31/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/26/2025	IFRX InflaRx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/21/2025	IFRX InflaRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/10/2025	ARCT Arcturus Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
3/10/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $68.00
3/7/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$63.00 ➝ $60.00
3/7/2025	ARCT Arcturus Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/7/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$58.00 ➝ $50.00
3/7/2025	IFRX InflaRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$138.39M	2.53	N/A	N/A	$10.42 per share	1.24
IFRX InflaRx	$165.79K	526.41	N/A	N/A	$1.89 per share	0.69
TRDA Entrada Therapeutics	$210.78M	1.58	N/A	N/A	$7.26 per share	1.22
TSHA Taysha Gene Therapies	$8.33M	43.31	N/A	N/A	$0.40 per share	4.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$3.01	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	5/12/2025 (Estimated)
IFRX InflaRx	-$46.18M	-$0.87	N/A	N/A	N/A	-33,362.70%	-65.98%	-56.86%	5/6/2025 (Estimated)
TRDA Entrada Therapeutics	-$6.68M	$1.91	5.56	N/A	N/A	25.53%	16.11%	10.39%	5/6/2025 (Estimated)
TSHA Taysha Gene Therapies	-$111.57M	-$0.36	2.79	N/A	N/A	-229.67%	-106.36%	-49.16%	5/13/2025 (Estimated)

Latest IFRX, TRDA, ARCT, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	IFRX InflaRx	-$0.18	N/A	N/A	N/A	$0.03 million	N/A
5/13/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	N/A	N/A	N/A	$1.48 million	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.10	N/A	N/A	N/A	$25.64 million	N/A
5/6/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	N/A	N/A	N/A	$10.98 million	N/A
3/20/2025	Q4 2024	IFRX InflaRx	-$0.27	-$0.09	+$0.18	-$0.09	$0.13 million	N/A
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million
2/27/2025	Q4 2024	TRDA Entrada Therapeutics	-$0.66	$0.03	+$0.69	$0.03	$11.95 million	$12.25 million
2/26/2025	Q4 2024	TSHA Taysha Gene Therapies	-$0.08	-$0.07	+$0.01	-$0.07	$2.05 million	$2.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	5.54%	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.76	4.76
IFRX InflaRx	N/A	5.31	4.61
TRDA Entrada Therapeutics	N/A	6.59	6.59
TSHA Taysha Gene Therapies	0.48	5.51	5.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
IFRX InflaRx	42.39%
TRDA Entrada Therapeutics	86.39%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	15.30%
IFRX InflaRx	16.30%
TRDA Entrada Therapeutics	7.59%
TSHA Taysha Gene Therapies	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
TRDA Entrada Therapeutics	110	37.60 million	34.58 million	Optionable
TSHA Taysha Gene Therapies	180	205.06 million	199.41 million	Optionable

IFRX, TRDA, ARCT, and TSHA Headlines

Recent News About These Companies

Avoro Capital Advisors LLC Buys 1,349,999 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

April 23, 2025 | marketbeat.com

B Group Inc. Buys Shares of 965,556 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

April 23, 2025 | marketbeat.com

Why Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 16.13%

April 22, 2025 | aaii.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co.

April 21, 2025 | marketbeat.com

Vanguard Group Inc. Raises Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

April 20, 2025 | marketbeat.com

Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity

April 16, 2025 | seekingalpha.com

Norges Bank Takes $2.53 Million Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

April 14, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Analysts

April 7, 2025 | marketbeat.com

Wells Fargo Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)

April 5, 2025 | markets.businessinsider.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 4, 2025 | globenewswire.com

Why Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Down 11.15%

April 1, 2025 | aaii.com

Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts?

March 19, 2025 | msn.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 7, 2025 | globenewswire.com

Truist Financial Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

February 28, 2025 | markets.businessinsider.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript

February 28, 2025 | msn.com

Q4 2024 Taysha Gene Therapies Inc Earnings Call

February 27, 2025 | finance.yahoo.com

Taysha Gene Therapies Reports 2024 Financial Results

February 27, 2025 | tipranks.com

Taysha Gene Therapies reports FY24 EPS (36c) vs (96c) last year

February 26, 2025 | markets.businessinsider.com

Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript

February 26, 2025 | seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates

February 26, 2025 | zacks.com

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

February 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX, TRDA, ARCT, and TSHA Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.91 +0.02 (+0.16%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$12.90 -0.01 (-0.04%)

As of 04/25/2025 05:46 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

InflaRx NASDAQ:IFRX

$1.30 -0.02 (-1.52%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.00 (+0.38%)

As of 04/25/2025 06:26 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Entrada Therapeutics NASDAQ:TRDA

$8.84 -0.12 (-1.34%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$8.85 +0.01 (+0.11%)

As of 04/25/2025 04:46 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Taysha Gene Therapies NASDAQ:TSHA

$1.76 -0.06 (-3.30%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$1.74 -0.02 (-1.14%)

As of 04/25/2025 05:56 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time